Home > Oncology > How neoadjuvant atezolizumab changes T-cell dynamics in early NSCLC

How neoadjuvant atezolizumab changes T-cell dynamics in early NSCLC

Expert
Dr Feliz Özkan, University of Essen, Germany
Conference
WCLC 2022
Trial
LCMC3
Neoadjuvant atezolizumab conferred increased specific T-cell clone expansion in the tumour compared with pre-treatment among patients with resectable stage IB to stage IIIB non-small cell lung cancer (NSCLC). These data were presented by Dr Feliz Özkan, interventional pulmonologist at the University of Essen, Germany, at the International Association for the Study of Lung Cancer World Conference on Lung Cancer (WCLC 2022) held in Vienna Austria, August 6 - 9, 2022 [1]. In turn, increased T-cell clone expansion which was associated with better pathologic response. Medicom interviewed Dr Özkan about the implications of her results.


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on